Horizon Therapeutics plc Reports Fourth-Quarter and Full-Yea

Fourth-Quarter 2022 Results: -- Net Sales of $942.0 Million -- -- GAAP Net Income of $120.4 Million; Adjusted EBITDA of $357.5 Million; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses

Related Keywords

Japan , United States , Ireland , Russia , Brazil , Ukraine , Irish , Dennis Riedl , Geoff Curtis , Tim Walbert , Tina Ventura , Ray Gordon , Erin Linnihan , Instagram , Amgen , Linkedin , Twitter , Nasdaq , Clinical Program Expected To , Alkem Laboratories Inc , Amgen Inc , Facebook , Corporate Affairs , Apotex Inc , Net Sales , Year Over Increase , Record Adjusted , Operating Cash Flow , Recent Company Highlights , Transaction Expected , Positive Topline Data , Second Population , Syndrome Phase , Only Phase , Syndrome Trial , Primary Endpoint , Both Patient Populations , Program Expected , Active Thyroid Eye Disease , Topline Results Expected , Topline Results , Low Clinical Activity Score , Adult Patients , Neuromyelitis Optica Spectrum , Daxdilimab Discoid Lupus Erythematosus Phase , Dermatitis Phase , Alkem Laboratories , Investor Relations , Regarding Use , Consolidated Statements , Months Ended December , Earnings Per Share , Per Share , Per Share Basic , Rate Reconciliation , Three Months Ended December , Twelve Months Ended December , Lake Forest , Vice President , Investor Relations Officer , Affairs Chief Communications Officer , Horizon , Herapeutics , Reports , Fourth , Quarter , Bull , Ear , 022 , Financial , Results ,